{"id":"any-biologic-treatment-for-psoriasis","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nasopharyngitis"},{"rate":"10-20%","effect":"Upper respiratory tract infection"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Injection site reaction"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IL-23 is a cytokine that plays a key role in the development of psoriasis. By blocking the IL-23 receptor, tildrakizumab reduces the production of pro-inflammatory molecules, leading to decreased inflammation and improved symptoms in patients with psoriasis.","oneSentence":"Tildrakizumab blocks the interaction between interleukin-23 (IL-23) and its receptor, reducing inflammation in the body.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:56:55.724Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Moderate to severe scalp psoriasis"}]},"trialDetails":[{"nctId":"NCT00508547","phase":"","title":"Psoriasis Longitudinal Assessment and Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2007-06-21","conditions":"Psoriasis","enrollment":15842},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT06587828","phase":"","title":"A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease","status":"RECRUITING","sponsor":"TScan Therapeutics, Inc.","startDate":"2023-01-03","conditions":"Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis","enrollment":300},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT04717466","phase":"PHASE4","title":"Brain Changes in Psoriasis After Secukinumab Treatment","status":"COMPLETED","sponsor":"University of Miami","startDate":"2021-06-29","conditions":"Psoriasis, Healthy","enrollment":20},{"nctId":"NCT06952465","phase":"","title":"A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-01-24","conditions":"Psoriasis","enrollment":2000},{"nctId":"NCT06055699","phase":"","title":"Association Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of Patients With pSOriasis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03-01","conditions":"Psoriasis, Microbial Colonization","enrollment":50},{"nctId":"NCT04325724","phase":"NA","title":"Evaluation of the Role of Inflammatory and Structural Ultrasound Abnormalities by Explaining the Perspective of Patients With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04","conditions":"Psoriatic Arthritis","enrollment":100},{"nctId":"NCT01555606","phase":"","title":"An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2011-06","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Any biologic treatment for psoriasis","genericName":"Any biologic treatment for psoriasis","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tildrakizumab blocks the interaction between interleukin-23 (IL-23) and its receptor, reducing inflammation in the body. Used for Moderate to severe plaque psoriasis, Moderate to severe scalp psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}